- Review Article
- Published:
Immunogenicity of CAR T cells in cancer therapy
- Dimitrios L. Wagner ORCID:orcid.org/0000-0002-2189-35791,2 na1,
- Enrico Fritsche1 na1,
- Michael A. Pulsipher3,
- Nabil Ahmed4,5,
- Mohamad Hamieh6,
- Meenakshi Hegde4,5,
- Marco Ruella7,8,
- Barbara Savoldo9,
- Nirali N. Shah ORCID:orcid.org/0000-0002-8474-908010,
- Cameron J. Turtle11,12,
- Alan S. Wayne13,14 &
- …
- Mohamed Abou-el-Enein1,15,16
Nature Reviews Clinical Oncologyvolume 18, pages379–393 (2021)Cite this article
18kAccesses
186Citations
74Altmetric
Abstract
Patient-derived T cells genetically reprogrammed to express CD19-specific chimeric antigen receptors (CARs) have shown remarkable clinical responses and are commercially available for the treatment of patients with certain advanced-stage B cell malignancies. Nonetheless, several trials have revealed pre-existing and/or treatment-induced immune responses to the mouse-derived single-chain variable fragments included in these constructs. These responses might have contributed to both treatment failure and the limited success of redosing strategies observed in some patients. Data from early phase clinical trials suggest that CAR T cells are also associated with immunogenicity-related events in patients with solid tumours. Generally, the clinical implications of anti-CAR immune responses are poorly understood and highly variable between different CAR constructs and malignancies. These observations highlight an urgent need to uncover the mechanisms of immunogenicity in patients receiving CAR T cells and develop validated assays to enable clinical detection. In this Review, we describe the current clinical evidence of anti-CAR immune responses and discuss how new CAR T cell technologies might impact the risk of immunogenicity. We then suggest ways to reduce the risks of anti-CAR immune responses to CAR T cell products that are advancing towards the clinic. Finally, we summarize measures that investigators could consider in order to systematically monitor and better comprehend the possible effects of immunogenicity during trials involving CAR T cells as well as in routine clinical practice.
Key points
Pre-existing and/or treatment-induced immunity to chimeric antigen receptor (CAR) constructs containing mouse-derived single-chain variable fragments are associated with treatment failure in certain patients and might limit the success of redosing strategies.
The possible effects of immunogenicity on CAR T cell persistence and function are currently poorly understood.
Novel technologies designed to enhance CAR T cell performance and/or the application of allogeneic CAR T cells might further amplify the likelihood of anti-CAR immune responses, thus necessitating strategies to overcome such risks.
Various monitoring, mitigation and management approaches can be used to reduce the risk of anti-CAR immunity, although validated assays enabling adequate assessments of anti-CAR immune responses remain an unmet need.
We advocate for the inclusion of CAR-associated immunogenicity analysis in both preclinical and clinical investigations of CAR T cell therapy.
This is a preview of subscription content,access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
9,800 Yen / 30 days
cancel any time
Subscription info for Japanese customers
We have a dedicated website for our Japanese customers. Please go tonatureasia.com to subscribe to this journal.
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
References
June, C. H. & Sadelain, M. Chimeric antigen receptor therapy.N. Engl. J. Med.379, 64–73 (2018).
Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy.Nat. Rev. Clin. Oncol.17, 147–167 (2020).
MacKay, M. et al. The therapeutic landscape for cells engineered with chimeric antigen receptors.Nat. Biotechnol.38, 233–244 (2020).
Elsallab, M., Levine, B. L., Wayne, A. S. & Abou-El-Enein, M. CAR T-cell product performance in haematological malignancies before and after marketing authorisation.Lancet Oncol.21, e104–e116 (2020).
Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.Sci. Transl. Med.4, 132ra53 (2012).
Brudno, J. N. & Kochenderfer, J. N. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management.Blood Rev.34, 45–55 (2019).
Fucá, G., Reppel, L., Landoni, E., Savoldo, B. & Dotti, G. Enhancing chimeric antigen receptor T cell efficacy in solid tumors.Clin. Cancer Res.26, 2444–2451 (2020).
Schmidts, A. & Maus, M. V. Making CAR T cells a solid option for solid tumors.Front. Immunol.9, 2593 (2018).
Jensen, M. C. et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.Biol. Blood Marrow Transplant.16, 1245–1256 (2010).
Lamers, C. H. J. et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.Blood117, 72–82 (2011).
Riddell, S. R. et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients.Nat. Med.2, 216–223 (1996).
Klee, G. G. Human anti-mouse antibodies.Arch. Pathol. Lab. Med.124, 921–923 (2000).
Blanco, I. et al. Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72.J. Clin. Immunol.17, 96–106 (1997).
Jaffers, G. J. et al. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression.Transplantation41, 572–578 (1986).
Sege, K. & Peterson, P. A. Use of anti-idiotypic antibodies as cell-surface receptor probes.Proc. Natl Acad. Sci. USA75, 2443–2447 (1978).
Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.Clin. Cancer Res.12, 6106–6115 (2006).
Maus, M. V. et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.Cancer Immunol. Res.1, 26–31 (2013).
Baudouin, V. et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti–interleukin-2 receptor monoclonal antibody basiliximab.Transplantation76, 459–463 (2003).
Awasthi, R. et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.Blood Adv.4, 560–572 (2020).
European Medicines Agency. EMA - Yescarta / axicabtagene ciloleucel - Assessment report.https://www.ema.europa.eu/en/documents/assessment-report/yescarta-epar-public-assessment-report_en.pdf (2018).
Mueller, K. T. et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia.Clin. Cancer Res.24, 6175–6184 (2018).
European Medicines Agency. EMA - Kymriah / tisagenlecleucel - Assessment Report.https://www.ema.europa.eu/en/documents/assessment-report/kymriah-epar-public-assessment-report_en.pdf (2018).
Kite Pharma. Kite Pharma - Tecartus / brexucabtagene autoleucel - Full prescribing information.https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel (2020).
Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.Nat. Med.25, 1408–1414 (2019).
Till, B. G. et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.Blood119, 3940–3950 (2012).
Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.Lancet385, 517–528 (2015).
Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.J. Clin. Invest.126, 2123–2138 (2016).
Turtle, C. J. et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.Sci. Transl. Med.8, 355ra116 (2016).
Brudno, J. N. et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.Nat. Med.26, 270–280 (2020).
Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.N. Engl. J. Med.378, 439–448 (2018).
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.N. Engl. J. Med.377, 2531–2544 (2017).
Mahadeo, K. M. et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.Nat. Rev. Clin. Oncol.16, 45–63 (2019).
Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy.Nat. Rev. Clin. Oncol.16, 372–385 (2019).
Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy.Cancer Discov.8, 1219–1226 (2018).
Gauthier, J. et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies.Bloodhttps://doi.org/10.1182/blood.2020006770 (2020).
Ali, S. A. et al. T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.Blood128, 1688–1700 (2016).
Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.J. Clin. Invest.129, 2210–2221 (2019).
Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.N. Engl. J. Med.380, 1726–1737 (2019).
Brudno, J. N. et al. T cells genetically modified to express an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma.J. Clin. Oncol.36, 2267–2280 (2018).
Xu, J. et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.Proc. Natl Acad. Sci. USA116, 9543–9551 (2019).
Yan, Z. et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.Lancet Haematol.6, e521–e529 (2019).
Zhao, W.-H. et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.J. Hematol. Oncol.11, 141 (2018).
Maciocia, P. M. et al. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.Nat. Med.23, 1416–1423 (2017).
Gomes-Silva, D. et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.Blood130, 285–296 (2017).
Rasaiyaah, J., Georgiadis, C., Preece, R., Mock, U. & Qasim, W. TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy.JCI Insight3, e99442 (2018).
Mamonkin, M., Rouce, R. H., Tashiro, H. & Brenner, M. K. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.Blood126, 983–992 (2015).
Hill, L. C. et al. Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed/refractory T-cell malignancies.Blood134, 199–199 (2019).
Hege, K. M. et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.J. Immunother. Cancer5, 22 (2017).
Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.Mol. Ther.21, 904–912 (2013).
Gonzales, N. Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.Mol. Immunol.40, 337–349 (2003).
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.Nat. Biotechnol.20, 70–75 (2002).
Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.Leukemia18, 676–684 (2004).
Savoldo, B. et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients.J. Clin. Invest.121, 1822 (2011).
Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.Sci. Transl. Med.3, 95ra73 (2011).
Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.N. Engl. J. Med.368, 1509–1518 (2013).
Ahmed, N. et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma.J. Clin. Oncol.33, 1688–1696 (2015).
Ahmed, N. et al. HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma.JAMA Oncol.3, 1094–1101 (2017).
Moritz, D., Wels, W., Mattern, J. & Groner, B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.Proc. Natl Acad. Sci. USA91, 4318–4322 (1994).
Wels, W., Harwerth, I. M., Mueller, M., Groner, B. & Hynes, N. E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor.Cancer Res.52, 6310–6317 (1992).
Hegde, M. et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma.Nat. Commun.11, 3549 (2020).
Gargett, T. et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade.Mol. Ther.24, 1135–1149 (2016).
Haas, A. R. et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers.Mol. Ther.27, 1919–1929 (2019).
Junghans, R. P. et al. Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response.Prostate76, 1257–1270 (2016).
Maude, S. L. et al. Durable remissions with humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in CAR-naive and CAR-exposed children and young adults with relapsed/refractory acute lymphoblastic leukemia.Blood130, 1319–1319 (2017).
Cao, J. et al. Potent anti-leukemia activities of humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.Am. J. Hematol.93, 851–858 (2018).
Zhao, Y. et al. Treatment with humanized selective CD19CAR-T cells shows efficacy in highly treated B-ALL patients who have relapsed after receiving murine-based CD19CAR-T therapies.Clin. Cancer Res.25, 5595–5607 (2019).
Holliger, P. & Hudson, P. J. Engineered antibody fragments and the rise of single domains.Nat. Biotechnol.23, 1126–1136 (2005).
Clarke, S. C. et al. Multispecific antibody development platform based on human heavy chain antibodies.Front. Immunol.9, 3037 (2019).
Li, N., Fu, H., Hewitt, S. M., Dimitrov, D. S. & Ho, M. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.Proc. Natl Acad. Sci. USA114, E6623–E6631 (2017).
Schneider, D. et al. A unique human immunoglobulin heavy chain variable domain-only CD33 CAR for the treatment of acute myeloid leukemia.Front. Oncol.8, 539 (2018).
Mikkilineni, L. et al. T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-only antigen recognition domain induce remissions in patients with relapsed multiple myeloma.Blood134, 3230–3230 (2019).
Lam, N. et al. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains.Nat. Commun.11, 283 (2020).
Zhang, T., Barber, A. & Sentman, C. L. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.Cancer Res.66, 5927–5933 (2006).
Frazao, A. et al. NKG2D/NKG2-ligand pathway offers new opportunities in cancer treatment.Front. Immunol.10, 661 (2019).
Deng, X. et al. Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo.Am. J. Cancer Res.9, 945–958 (2019).
Kahlon, K. S. et al. Specific recognition and killing of glioblastoma multiforme by interleukin 13-Zetakine redirected cytolytic T cells.Cancer Res.64, 9160–9166 (2004).
Sengupta, S., Thaci, B., Crawford, A. C. & Sampath, P. Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.BioMed. Res. Int.2014, 952128 (2014).
Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy.N. Engl. J. Med.375, 2561–2569 (2016).
Pameijer, C. R. J. et al. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor.Cancer Gene Ther.14, 91–97 (2007).
Whilding, L. M. et al. Targeting of aberrant αvβ6 integrin expression in solid tumors using chimeric antigen receptor-engineered T cells.Mol. Ther.25, 259–273 (2017).
Muniappan, A., Banapour, B., Lebkowski, J. & Talib, S. Ligand-mediated cytolysis of tumor cells: use of heregulin-ζ chimeras to redirect cytotoxic T lymphocytes.Cancer Gene Ther.7, 128–134 (2000).
Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses.Cell173, 1426–1438.e11 (2018).
Lohmueller, J. J., Ham, J. D., Kvorjak, M. & Finn, O. J. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting.Oncoimmunology7, e1368604 (2017).
Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.Clin. Cancer Res.19, 3153–3164 (2013).
Guest, R. D. et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors.J. Immunother.28, 203–211 (2005).
Till, B. G. et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.Blood112, 2261–2271 (2008).
Jonnalagadda, M. et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid Fc receptor binding and improve T cell persistence and antitumor efficacy.Mol. Ther.23, 757–768 (2015).
Hombach, A., Hombach, A. A. & Abken, H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response.Gene Ther.17, 1206–1213 (2010).
Shum, T., Kruse, R. L. & Rooney, C. M. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.Expert Opin. Biol. Ther.18, 653–664 (2018).
Conlon, K. C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.J. Clin. Oncol.33, 74–82 (2015).
Chen, Y. et al. Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15.Clin. Cancer Res.25, 2915–2924 (2019).
Hu, B. et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18.Cell Rep.20, 3025–3033 (2017).
Ma, X. et al. Interleukin-23 engineering improves CAR T cell function in solid tumors.Nat. Biotechnol.38, 448–459 (2020).
Kim, T.-S. & Shin, E.-C. The activation of bystander CD8+ T cells and their roles in viral infection.Exp. Mol. Med.51, 1–9 (2019).
Pacheco, Y. et al. Bystander activation and autoimmunity.J. Autoimmun.103, 102301 (2019).
Heczey, A. et al. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.Nat. Med.26, 1686–1690 (2020).
Shum, T. et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells.Cancer Discov.7, 1238–1247 (2017).
Kagoya, Y. et al. A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects.Nat. Med.24, 352–359 (2018).
Berger, C., Flowers, M. E., Warren, E. H. & Riddell, S. R. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.Blood107, 2294–2302 (2006).
Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy.N. Engl. J. Med.365, 1673–1683 (2011).
Zhou, X. et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.Blood125, 4103–4113 (2015).
Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.Blood118, 1255–1263 (2011).
Arber, C. et al. The immunogenicity of virus-derived 2A sequences in immunocompetent individuals.Gene Ther.20, 958–962 (2013).
Mizuguchi, H., Xu, Z., Ishii-Watabe, A., Uchida, E. & Hayakawa, T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector.Mol. Ther.1, 376–382 (2000).
Wiebking, V. et al. Metabolic engineering generates a transgene-free safety switch for cell therapy.Nat. Biotechnol.38, 1441–1450 (2020).
Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition.Clin. Cancer Res.23, 2255–2266 (2017).
Lu, Y. et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.Nat. Med.26, 732–740 (2020).
Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer.Science367, eaba7365 (2020).
Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells.Sci. Transl. Med.9, eaaj2013 (2017).
Torikai, H. et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.Blood122, 1341–1349 (2013).
Kagoya, Y. et al. Genetic ablation of HLA class I, class II, and the T cell receptor enables allogeneic T cells to be used for adoptive T cell therapy.Cancer Immunol. Res.8, 926–936 (2020).
Charlesworth, C. T. et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans.Nat. Med.25, 249–254 (2019).
Simhadri, V. L. et al. Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population.Mol. Ther. Methods Clin. Dev.10, 105–112 (2018).
Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells.Nat. Biotechnol.31, 822–826 (2013).
Zhang, X.-H., Tee, L. Y., Wang, X.-G., Huang, Q.-S. & Yang, S.-H. Off-target effects in CRISPR/Cas9-mediated genome engineering.Mol. Ther. Nucleic Acids4, e264 (2015).
Abou-El-Enein, M. et al. Human genome editing in the clinic: new challenges in regulatory benefit-risk assessment.Cell Stem Cell21, 427–430 (2017).
Wagner, D. L. et al. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population.Nat. Med.25, 242–248 (2019).
Li, A. et al. AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9.Mol. Ther.28, 1432–1441 (2020).
Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges.Nat. Rev. Drug Discov.19, 185–199 (2020).
Suchin, E. J. et al. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question.J. Immunol.166, 973–981 (2001).
DeWolf, S. et al. Quantifying size and diversity of the human T cell alloresponse.JCI Insight3, e121256 (2018).
Spierings, E. et al. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.Biol. Blood Marrow Transplant.19, 1244–1253 (2013).
Benjamin, R. et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.Lancet396, 1885–1894 (2020).
Gornalusse, G. G. et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells.Nat. Biotechnol.35, 765–772 (2017).
Xu, H. et al. Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility.Cell Stem Cell24, 566–578.e7 (2019).
Lanza, R., Russell, D. W. & Nagy, A. Engineering universal cells that evade immune detection.Nat. Rev. Immunol.19, 723–733 (2019).
Deuse, T. et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients.Nat. Biotechnol.37, 252–258 (2019).
Mo, F. et al. Engineered off-the-shelf therapeutic T cells resist host immune rejection.Nat. Biotechnol.39, 56–63 (2021).
Muranski, P. et al. Increased intensity lymphodepletion and adoptive immunotherapy — how far can we go?Nat. Clin. Pract. Oncol.3, 668–681 (2006).
Miller, J. S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.Blood105, 3051–3057 (2005).
Tzannou, I. et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation.J. Clin. Oncol.35, 3547–3557 (2017).
Leen, A. M. et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.Blood121, 5113–5123 (2013).
Melenhorst, J. J. et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.Blood116, 4700–4702 (2010).
Pule, M. A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.Nat. Med.14, 1264–1270 (2008).
Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors.N. Engl. J. Med.382, 545–553 (2020).
Heczey, A. et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.Blood124, 2824–2833 (2014).
Deniger, D. C. et al. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.Mol. Ther.21, 638–647 (2013).
Yakoub-Agha, I. et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).Haematologica105, 297–316 (2020).
Kansagra, A. J. et al. Clinical utilization of chimeric antigen receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) – an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).Bone Marrow Transpl.54, 1868–1880 (2019).
Jain, T. et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy.Biol. Blood Marrow Transpl.25, 2305–2321 (2019).
Ramos, C. A. et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.J. Clin. Invest.127, 3462–3471 (2017).
Potthoff, B., McBlane, F., Spindeldreher, S. & Sickert, D. A cell-based immunogenicity assay to detect antibodies against chimeric antigen receptor expressed by tisagenlecleucel.J. Immunol. Methods476, 112692 (2020).
Jahn, E.-M. & Schneider, C. K. How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations.N. Biotechnol.25, 280–286 (2009).
European Medicines Agency. Immunogenicity assessment of biotechnology-derived therapeutic proteins (EMEA/CHMP/BMWP/14327/2006).https://www.ema.europa.eu/en/immunogenicity-assessment-biotechnology-derived-therapeutic-proteins (2018).
Shankar, G. et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.AAPS J.16, 658–673 (2014).
US Food and Drug Administration. Immunogenicity Testing of Therapeutic Protein Products — Developing and Validating Assays for Anti-Drug Antibody Detection (FDA-2009-D-0539; 03/15/2019).https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug (2020).
Zhang, H. et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.Nat. Med.11, 1238–1243 (2005).
Maude, S. L. et al. Efficacy and safety of humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 in children with relapsed/refractory ALL.Blood126, 683 (2015).
Li, M.-Y. et al. Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transplantation: a case report.Biomark. Res.8, 36 (2020).
Shah, N. N. et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial.J. Clin. Oncol.38, 1938–1950 (2020).
Pan, J. et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.Leukemia33, 2854–2866 (2019).
Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.Nat. Med.24, 20–28 (2018).
Yang, Y. & Wilson, J. M. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo.J. Immunol.155, 2564–2570 (1995).
Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response.Nat. Rev. Immunol.12, 269–281 (2012).
Scott, A. M., Allison, J. P. & Wolchok, J. D. Monoclonal antibodies in cancer therapy.Cancer Immunol. Res. 12 (2012).
Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.Blood119, 2709–2720 (2012).
Beatty, G. L. et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.Cancer Immunol. Res.2, 112–120 (2014).
Acknowledgements
The work of N.A. and M.H. is supported by the US NIH PHS grant U54-CA23256 and by Stand Up to Cancer–St Baldrick’s Paediatric Dream Team Translational Research Grant (SU2C-AACR-DT1113). The work of A.S.W. is supported by the US National Cancer Institute [P30CA014089]. The content of this publication does not necessarily reflect the views of policies of the Department of Health and Human Services nor does its mention of trade names, commercial products or organizations imply endorsement by the U.S. Government. The authors thank Catherine Gillespie (Baylor College of Medicine, USA) for her assistance in editing the manuscript and thank Naomi Taylor and Christopher Chien (Pediatric Oncology Branch, National Cancer Institute, NIH, USA) for their critical review of the figures.
Review criteria
We conducted a literature screen and identified 120 clinical trial publications describing the use of chimeric antigen receptor (CAR) T cells, out of which 34 reported on the investigation of immunogenicity using laboratory assays (Box 1). A complete list of these trials, including information on the assays used to characterize immunogenicity, CAR design, trial outcomes and preconditioning regimens, is available in Supplementary Table1. Data cut-off July 15, 2020.
Author information
These authors contributed equally: Dimitrios L. Wagner, Enrico Fritsche.
Authors and Affiliations
Berlin Center for Advanced Therapies (BeCAT) and Berlin Institute of Health (BIH) Center for Regenerative Therapies (BCRT), Charité – Universitätsmedizin Berlin, Berlin, Germany
Dimitrios L. Wagner, Enrico Fritsche & Mohamed Abou-el-Enein
Institute of Transfusion Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
Dimitrios L. Wagner
Section of Transplantation and Cellular Therapy, Children’s Hospital Los Angeles Cancer and Blood Disease Institute, USC Keck School of Medicine, Los Angeles, CA, USA
Michael A. Pulsipher
Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Houston, TX, USA
Nabil Ahmed & Meenakshi Hegde
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA
Nabil Ahmed & Meenakshi Hegde
Center for Cell Engineering and Immunology Program, Sloan Kettering Institute, New York, NY, USA
Mohamad Hamieh
Center for Cellular Immunotherapies, University of Pennsylvania Philadelphia, Philadelphia, PA, USA
Marco Ruella
Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Marco Ruella
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
Barbara Savoldo
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Nirali N. Shah
Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
Cameron J. Turtle
Department of Medicine, University of Washington, Seattle, WA, USA
Cameron J. Turtle
Cancer and Blood Disease Institute, Division of Hematology-Oncology, Children’s Hospital Los Angeles, Los Angeles, CA, USA
Alan S. Wayne
Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Alan S. Wayne
Division of Medical Oncology, Department of Medicine, and Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Mohamed Abou-el-Enein
Joint USC/CHLA Cell Therapy Program, University of Southern California, and Children’s Hospital Los Angeles, Los Angeles, CA, USA
Mohamed Abou-el-Enein
- Dimitrios L. Wagner
You can also search for this author inPubMed Google Scholar
- Enrico Fritsche
You can also search for this author inPubMed Google Scholar
- Michael A. Pulsipher
You can also search for this author inPubMed Google Scholar
- Nabil Ahmed
You can also search for this author inPubMed Google Scholar
- Mohamad Hamieh
You can also search for this author inPubMed Google Scholar
- Meenakshi Hegde
You can also search for this author inPubMed Google Scholar
- Marco Ruella
You can also search for this author inPubMed Google Scholar
- Barbara Savoldo
You can also search for this author inPubMed Google Scholar
- Nirali N. Shah
You can also search for this author inPubMed Google Scholar
- Cameron J. Turtle
You can also search for this author inPubMed Google Scholar
- Alan S. Wayne
You can also search for this author inPubMed Google Scholar
- Mohamed Abou-el-Enein
You can also search for this author inPubMed Google Scholar
Contributions
D.L.W., E.F. and M.A. researched data for the manuscript. All authors made a contribution to discussions of content. D.L.W., E.F., M.A.P., N.A., M.H.a., M.H.e., B.S., N.N.S., C.J.T., A.S.W. and M.A. wrote the manuscript. All authors edited and/or reviewed the manuscript prior to submission.
Corresponding author
Correspondence toMohamed Abou-el-Enein.
Ethics declarations
Competing interests
M.A.P. has acted as an advisor for Mesoblast and Novartis, has received research funding from Adaptive and Miltenyi, and has received honoraria for educational activities from Miltenyi and Novartis. N.A. has acted as a consultant for Adaptimmune and continues to consult for Equillium (pro bono) and The Children’s Cancer Hospital Egypt 57357 on medical education and research development, has received one-time royalties from Celgene and Cell Medica, and is a named inventor on patents and patent applications in the field of chimeric antigen receptor (CAR) T cell therapy owned by Baylor College of Medicine. M. Hamieh is listed on patents relating to CAR technologies and has received royalties from Atara Biotherapeutics, Fate Therapeutics and Takeda Pharmaceuticals. M. Hegde is a named inventor on patents and patent applications in the field of CAR T cell therapy owned by Baylor College of Medicine. M.R. has acted as a consultant of AbClon, Bristol-Myers Squibb (BMS), Mesoblast, NanoString, and Novartis, has received research support from Adaptive and Miltenyi, and is listed on patents relating to CAR technologies and receives royalties from Novartis and Tmunity. B.S. has acted as a consultant of Tessa Therapeutics, has received research funding from Bellicum Pharmaceuticals, Bluebird Bio, Cell Medica and Tessa Therapeutics, and is listed on patents in the field of CAR and T cell receptor (TCR) therapy. C.J.T. has served on the scientific advisory boards of ArsenalBio, Caribou Biosciences, Century Therapeutics, Eureka Therapeutics, Myeloid Therapeutics, Precision Biosciences and T-CURX, has acted as an ad hoc consultant of Allogene, Amgen, AstraZeneca, Nektar Therapeutics and PACT Pharma, has stock/options in ArsenalBio, Caribou Biosciences, Eureka Therapeutics, Myeloid Therapeutics and Precision Biosciences, has received research funding from AstraZeneca, Juno Therapeutics/BMS, Minerva, Nektar Therapeutics and TCR2 Therapeutics, and is listed on a patent licensed to Juno Therapeutics. A.S.W. has received research support from Kite Pharma and Institut de Recherches Internationales Servier. E.F., D.L.W., N.N.S. and M.A. declare no competing interests.
Additional information
Peer review information
Nature Reviews Clinical Oncology thanks Marcela Maus and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Wagner, D.L., Fritsche, E., Pulsipher, M.A.et al. Immunogenicity of CAR T cells in cancer therapy.Nat Rev Clin Oncol18, 379–393 (2021). https://doi.org/10.1038/s41571-021-00476-2
Accepted:
Published:
Issue Date:
